T-beta-RIII joins the fight against breast cancer
Although the soluble factor TGF-beta has been shown to suppress the growth of tumor cells in the early stages of breast cancer, high levels of TGF-beta during the later stages of the disease are associated with a poor outcome. A study using human breast cancer samples and mice, which appears online on December 7 in advance of publication in the January print issue of the Journal of Clinical Investigation, indicates that changes in expression of one component of the TGF-beta receptor, T-beta-RIII, might provide a mechanism for the distinct effects of TGF-beta at the different stages of breast cancer.
Gerard Blobe and colleagues from Duke University showed that expression of T-beta-RIII by human breast cancer samples markedly decreased or was lost with disease progression. Conversely, in a mouse model of breast cancer, tumor cells engineered to express high levels of T-beta-RIII were less able to invade the breast tissue and to metastasize to other organs than tumor cells not engineered to express this protein. Further analysis revealed that the mechanism behind these protective effects of T-beta-RIII was likely to be T-beta-RIII cleavage at the cell membrane, which releases soluble T-beta-RIII that blocks TGF-beta signaling. As low levels of T-beta-RIII were found to be associated with decreased recurrence-free survival of patients with breast cancer and loss of T-beta-RIII was found to begin before tumors became invasive, the authors suggest that analysis of T-beta-RIII levels might help clinicians decide how aggressively to treat their patients.
TITLE: The type III TGF-beta receptor suppresses breast cancer progression
Gerard C. Blobe
Duke University Medical Center, Durham, North Carolina, USA.
Phone: (919) 668-1352; Fax: (919) 668-2458; E-mail: [email protected].
View the PDF of this article at: https://www.the-jci.org/article.php?id=29293
Last reviewed: By John M. Grohol, Psy.D. on 30 Apr 2016
Published on PsychCentral.com. All rights reserved.